Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
The study is a single center,open label trial. To obtain safety information on toxicities
and adverse events attributable to the subcutaneous injections of autologous dendritic
cells incubated with irradiated autologous tumor stem cells and suspended in GM-CSF in
patients with HCC.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Vital signs，physical examinations and adverse events
The number of adverse events along with the results of vital signs measurements, physical examinations, and clinical laboratory tests will be used to determine the safety profile of DC-TC.
Shanghai 85 Hospital
China: Ministry of Health